Gene Logic and Roche Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
Gene Logic Inc. announced that it has entered into a drug repositioning and development agreement with Roche to seek alternative development paths for multiple Roche drug candidates. All of these drug candidates have successfully passed Phase I human clinical trials, and were discontinued in Phase II or Phase III clinical trials.
Similar to development-stage in-licensing deals, the agreement provides for Gene Logic to receive success-based milestone payments for each drug candidate Roche returns to clinical development. In addition, Gene Logic will receive royalties for each marketed drug. The agreement also provides Gene Logic the option to receive an exclusive license to any drug candidate that Roche chooses not to pursue, in which case Roche will receive success-based milestone and royalty payments.
Gene Logic's Drug Repositioning Program seeks to find alternative development paths for drug candidates with good safety records that have been de-prioritized or discontinued in Phase II or Phase III clinical trials. The program offers pharmaceutical partners a novel approach to bolster their late-stage pipelines with safe, high-quality drug candidates that originated from their own R&D efforts. In cases where the partner decides not to pursue development of a successfully repositioned compound, Gene Logic may have an option to develop or out-license the given drug candidate.
Other news from the department business & finance
